EUCTR2013-000180-81-GB进行中（未招募）1 期
A single-arm, open-label, multicentre, non-randomised, study to assess the effect and tolerability of standardised laxative therapy (SLT) for the reversal of opioid-induced constipation (OIC) in subjects suffering from malignant or non-malignant pain that requires around-the-clock opioid therapy.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 118
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects at least 18 years
- •2. Females less than one year post-menopausal must have a negative pregnancy test prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. (A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some intrauterine devices ((IUDs), hormonal), sexual abstinence or vasectomised partner).
- •3. Documented history of malignant or non-malignant pain that requires around-the-clock opioid therapy (WHO step II/III opioid analgesics).
- •4. Subjects treated with WHO step II/III opioid analgesics for at least 2 weeks prior to Screening Visit (Visit 1), who will continue with the opioid(s) over the proposed study period.
- •5. Subjects meeting the following criteria for OIC:
- •Subject and Investigator confirm that the Subject’s constipation is induced, or worsened by the Subject’s opioid medication (present at Screening)
- •Subjects with mean BFI score > 30 at Visit 1
- •Subjects with < 3 complete bowel movements (CBMs) in the week preceding the Visit 1, based on Subject’s retrospective memory in response to Investigator’s question
- •6. Subjects taking at least one laxative on regular basis (i.e. on at least =2 intakes per week during the =2 weeks prior to screening) for the treatment of OIC.
- •7. Subjects must be willing to take SLT.
- •8. Subjects taking daily natural dietary fibre supplementation are eligible if they can maintain their diet throughout the study, and in the Investigator’s opinion are willing and able to maintain adequate hydration.
- •9. Subjects must be willing and able (e.g. mental and physical condition) to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
- •10. In the Investigator’s opinion the Subject’s concomitant medication dose will remain stable throughout the study Period (here concomitant medications mean all medications besides opioids (standard and rescue opioid treatment)).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 59
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 59
排除标准
- •Medical Conditions:
- •1. In the Investigator’s opinion any contraindication and precautionary condition for laxative medication(s) used in the study as per the SmPC.
- •2. Subjects having any potential non-opioid cause of bowel dysfunction that might be a major contributor to the constipation (Refer Appendix 18.4 for examples).
- •3. Surgery within 2 months prior to the start of the Screening Visit (Visit 1), or planned surgery during the Screening and Treatment periods that may affect GI motility.
- •4. Subjects with colostomy or ileostomy.
- •5. Hospitalisation expected/planned within the study Period (e.g. planned hospitalisation for the treatment of a pre-existing condition before informed consent) which can affect the outcome measure analysis.
- •Treatments/Medications:
- •6. Subjects presently taking, or who have taken opioid antagonists (e.g. naloxone, naltrexone and methylnaltrexone) or opioid antagonists containing products (e.g. oxycodone/naloxone, buprenorphine/naloxone, pentazocine/naloxone, tilidine/naloxone) = 30 days prior to the start of the Screening Period.
- •7. Subjects already taking maximum daily dose of country specific SLT (both First and Second Line SLT) on a regular basis (i.e. =4 days per week) for the treatment of OIC.
- •8. Subjects receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine).
- •Additional Screening Exclusion Criteria for Subjects Suffering from Non-malignant Pain:
- •9. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as Visit 1).
- •Additional Screening Exclusion Criteria for Subjects Suffering from Malignant Pain:
- •10. Subjects who have received a new chemical entity or an experimental drug within 30 days of study entry (defined as Visit 1). Concurrent participation in another clinical trial is not permitted except the epidemiological study performed to assess the long-term survival data.
- •11. Subjects with an expected life expectancy of =3 months.
研究者
相似试验
撤回
4 期
A single-arm, open-label, multicentre, non-randomised, study to assess the effect and tolerability of standardised laxative therapy (SLT) for the reversal of opioid-induced constipation (OIC) in subjects suffering from malignant or non-malignant pain that requires around-the-clock opioid therapy.constipationOpioid-induced constipation and malignant and non-malignant paingastrointestinal obstructionNL-OMON39001Mundipharma30
进行中（未招募）
不适用
A study to evaluate the effect and tolerability of laxatives (medicines against constipation) for the reversal of constipation caused by opioids (medicines against pain)Assess the effect and tolerability of standardised laxative therapy (SLT) for the reversal of opioid-induced constipation (OIC) in subjects suffering from malignant or non-malignant pain that requires around-the-clock opioid therapyMedDRA version: 16.1Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856EUCTR2013-000180-81-SEMundipharma Research GmbH & Co. KG118
已完成
3 期
Trial to evaluate 3mg dose of Covid Vaccine of Cadila healthcare LimitedCTRI/2021/10/037137Cadila Healthcare Limited3,000
已完成
3 期
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to OfatumumabRelapsing Multiple SclerosisMSLBCTR2021034775ovartis Pharma Services Inc.15
已完成
Unknown
A clinical trial to evaluate the efficacy and safety of CareSens Air, a continuous glucose monitor, in adult patients with diabetes.Endocrine, nutritional and metabolic diseasesKCT0009215i-sens85